

hospitals in the Mountain West. The treatment regimens and outcomes in this population may inform approaches to current management and future clinical trials.

**Disclosure:** Dr. Wright has nothing to disclose. The institution of an immediate family member of Dr. Liu has received research support from NIH. The institution of Mr. Wong has received research support from Biogen Idec. Mr. Mizenko has nothing to disclose. The institution of Dr. Kammeyer has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Genentech. The institution of Dr. Schreiner has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for CDC. Dr. Schreiner has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Schreiner has received personal compensation in the range of \$500-\$4,999 for serving as an Expert Witness for Mary C Bush, LLC. The institution of Dr. Schreiner has received research support from Biogen. The institution of Dr. Schreiner has received research support from Roche Genentech. Dr. Kadish has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. The institution of Dr. Kadish has received research support from Alexion Pharmaceuticals. Dr. Smith has nothing to disclose. Dr. Galli has nothing to disclose. An immediate family member of Ms. Klein has received personal compensation for serving as an employee of Amgen. An immediate family member of Ms. Klein has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Amgen. Dr. Greenlee has received personal compensation in the range of \$500-\$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Medlink. Dr. Greenlee has received publishing royalties from a publication relating to health care. Dr. Greenlee has received publishing royalties from a publication relating to health care. The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH. The institution of Dr. Rose has received research support from Friend's of MS. The institution of Dr. Rose has received research support from Biogen. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care. Dr. Paz Soldan has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Paz Soldan has received research support from National Institutes of Health. The institution of Dr. Paz Soldan has received research support from National Multiple Sclerosis Society. The institution of Dr. Paz Soldan has received research support from Western Institute for Biomedical Research. The institution of Dr. Paz Soldan has received research support from Biogen. The institution of Dr. Paz Soldan has received research support from Novartis. The institution of Dr. Paz Soldan has received research support from Clene Nanomedicine. Dr. Bennett has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Horizon Therapeutics. Dr. Bennett has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Alexion. Dr. Bennett has received personal compensation in the range of \$10,000-\$49,999 for serving as a Consultant for Genentech-Roche. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for TG Therapeutics. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Reistone Bio. Dr. Bennett has received personal compensation in the range of \$5,000-\$9,999 for serving as a Consultant for Abbvie. Dr. Bennett has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Novartis. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Chugai. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Mitsubishi Tanabe. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Clene Nanomedicine. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Bennett has received personal compensation in the range of \$500-\$4,999 for serving as an Expert Witness for Parker, Whiteford Taylor. Dr. Bennett has received personal compensation in the range of \$5,000-\$9,999 for serving as an Expert Witness for Podoll. Dr. Bennett has received personal compensation in the range of \$5,000-\$9,999 for serving as an Expert Witness for Hogan Lovells. The institution of Dr. Bennett has received research support from Novartis. The institution of Dr. Bennett has received research support from Alexion. Dr. Bennett has received intellectual property interests from a discovery or technology relating to health care. Dr. Bennett has received publishing royalties from a publication relating to health care. Dr. Bonkowsky has received personal compensation in the range of \$500-

\$4,999 for serving as a Consultant for Bluebird bio. Dr. Bonkowsky has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Neurogene. Dr. Bonkowsky has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Passage Bio. Dr. Bonkowsky has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Takeda. Dr. Bonkowsky has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Autobahn. Dr. Bonkowsky has received stock or an ownership interest from Orchard. The institution of Dr. Bonkowsky has received research support from NIH. An immediate family member of Dr. Bonkowsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Bonkowsky has received publishing royalties from a publication relating to health care. The institution of Dr. Peterson has received research support from Kronus. The institution of Dr. Piquet has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Genentech. Dr. Piquet has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Piquet has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Piquet has received research support from Rocky Mountain MS Center. The institution of Dr. Piquet has received research support from Novartis. The institution of Dr. Piquet has received research support from Abbvie. The institution of Dr. Piquet has received research support from Roche/Genentech. The institution of Dr. Piquet has received research support from NYU. Dr. Piquet has received publishing royalties from a publication relating to health care. Dr. Piquet has received publishing royalties from a publication relating to health care. Dr. Piquet has received personal compensation in the range of \$5,000-\$9,999 for serving as a Litigative Consultant with US-Dept HHS/DICP. Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Clarion. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for ExpertConnect. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for VielaBio. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for Genentech. The institution of Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Consultant for Alexion. The institution of Dr. Clardy has received personal compensation in the range of \$0-\$499 for serving as a Consultant for GuidePoint. Dr. Clardy has received personal compensation in the range of \$10,000-\$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from Alexion Pharma. The institution of Dr. Clardy has received research support from Sumaira Foundation for NMO. The institution of Dr. Clardy has received research support from Immune Deficiency Foundation. The institution of Dr. Clardy has received research support from Western Institute for Veteran Research. The institution of Dr. Clardy has received research support from NIH/NINDS. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Grand Rounds Travel and Lodging with U of Iowa. Dr. Clardy has received personal compensation in the range of \$500-\$4,999 for serving as a Speaker Honoraria for Grand Rounds with Barrow Neurological Institute.

## A Case of Recurrent Cerebral Cortical Encephalitis in MOG Antibody-Associated Disease

Laura Cacciaguerra, John J. Chen, Eoin P. Flanagan

### Objective

NA.

### Background

Cerebral cortical encephalitis is a recently recognized syndrome of myelin-oligodendrocyte-glycoprotein-antibody-associated disease (MOGAD), yet most descriptions report single episodes without recurrence.

### Design/Methods

Case report of recurrent cerebral cortical encephalitis in MOGAD.

## Results

This is a case report of a 32-year-old patient who initially developed meningoencephalitis when he was three. He was stable until age 31, when he developed headaches followed by status epilepticus secondary to cerebral cortical encephalitis with accompanying unilateral right temporal cerebral cortical T2-hyperintensity with leptomeningeal enhancement. Cerebrospinal fluid analysis revealed 505 white cells/ $\mu$ l (normal, 0-5) but oligoclonal bands were negative. Over the subsequent two weeks he developed bilateral severe vision loss (20/400 bilaterally) accompanied by bilateral optic disc edema, and MRI orbits showed bilateral anterior segment optic nerve enhancement extending >50% of the length of each nerve, confirming bilateral optic neuritis. MOG-IgG was tested in serum and was positive at a titer of 1:100. He was treated with intravenous methylprednisolone 1 gram daily for 5 days and a subsequent slow oral prednisone taper along with anti-epileptic treatment with levetiracetam, later transitioned to oxcarbazepine, although he later self-discontinued all anti-epileptics. He received maintenance intravenous immunoglobulins (IVIg) 0.4 g/Kg weekly, that was later weaned to 1 g/Kg every 4 weeks. He then developed recurrent cerebral cortical encephalitis 18 months after his prior episode manifesting with seizures and left occipito-temporal T2-hyperintensity and swelling with leptomeningeal enhancement. He was treated with high dose IV steroids, an oral prednisone taper and his IVIg dose was changed back to 0.4 g/Kg once weekly and anti-seizure medications reinitiated.

## Conclusions

Cerebral cortical encephalitis in MOGAD can be recurrent. Close scrutiny of the MRI in patients with MOGAD who develop seizures after prior cerebral cortical encephalitis is important as it can discriminate a recurrent cerebral cortical encephalitis attack from a breakthrough seizure related to prior damage.

**Disclosure:** Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for BMS Celgene. Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Sanofi. John Chen has nothing to disclose. The institution of Dr. Flanagan has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Flanagan has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received research support from Viela Bio. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities.

## Development of New or Enlarging MRI Lesions Outside of Clinical Attacks in MOG-Antibody-Associated Disease

Stephanie Syc-Mazurek, John Chen, Padraig Morris, Elia Sechi, Jayawant Mandrekar, Jan-Mendelt Tillema, Alfonso Lopez, Claudia Lucchinetti, Nicholas Zalewski, Laura Cacciaguerra, Marina Buciu, Karl Krecke, Steven Messina, M. Tariq Bhatti, Sean Pittock, Eoin Flanagan

## Objective

To determine the frequency of new/enlarging T2 or enhancing asymptomatic lesions in myelin-oligodendrocyte-glycoprotein-antibody-associated-disease (MOGAD) and compare to multiple sclerosis (MS) and aquaporin-4 antibody-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD).

## Background

Data on new asymptomatic lesions in MOGAD is limited.

## Design/Methods

We retrospectively identified Mayo Clinic MOGAD patients with inclusion criteria of: 1) MOG-IgG positivity by live-cell-based-assay; 2) Fulfilling current MOGAD diagnostic criteria; 3) Baseline and follow-up paired MRIs without interval attacks. Paired MRIs (baseline and follow-up) were categorized as either attack-to-remission or remission-to-remission scans. A neurologist and neuroradiologist reviewed MRIs (T2-FLAIR brain, T2 spine, and T1-post-gadolinium brain and spine) to identify new/enlarging lesions. A subset of MOGAD patients matched for follow-up interval were compared to MS and AQP4+NMOSD patients.

## Results

We included 105 MOGAD patients (median age, 31 years [range, 3-80]; 60% female) with 373 paired MRIs (brain, 213, spine 160). In total, 13/373 (3%) scans (10/105 patients) had one or more new/enlarging T2-lesions (brain, 12/213 [5.6%]; spine, 1/160 [0.6%]) and 8/367 (2%) had enhancing lesions. New spinal lesions were rare across all groups (0-4%). T2 lesions occurred more commonly in attack-remission scans (8/171 [4.7%]) than remission-remission scans (5/202 [2.4%]). Clinical characteristics did not differ between patients who developed new/enlarging lesions and those who did not. Maintenance immunosuppressants were used in 44/105 (42%) patients. New/enlarging lesions did not predict future clinical relapse. New brain lesions were less in MOGAD (1/25 [4%]) than MS (14/26 [54%],  $p < 0.0001$ ) but did not differ from AQP4+NMOSD (1/13 [8%],  $p = 1.0$ ) in subgroup analysis.

## Conclusions

New brain MRI lesions rarely develop outside of attacks in MOGAD which differs from MS. Surveillance MRI in MOGAD may have limited utility as a surrogate biomarker of disease activity in clinical practice and for clinical trials.

**Disclosure:** Dr. Syc-Mazurek has nothing to disclose. John Chen has nothing to disclose. Padraig Morris has received publishing royalties from a publication relating to health care. Dr. Sechi has nothing to disclose. Dr. Mandrekar has nothing to disclose. Dr. Tillema has nothing to disclose. Dr. Lopez has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Lopez has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Lucchinetti has received personal compensation in the range of \$500-\$4,999 for serving as an officer or member of the Board of Directors for Mayo Clinic. The institution of Dr. Lucchinetti has received research support from Biogen Idec. The institution of Dr. Lucchinetti has received research support from NIH/NINDS. The institution of Dr. Lucchinetti has received research support from National Institute of Neurological Disorders and Stroke. The institution of Dr. Lucchinetti has received research support from National Multiple Sclerosis Society. Dr. Lucchinetti has received intellectual property interests from a discovery or technology relating to health care. Dr. Lucchinetti has a non-compensated relationship as a Member with National Institute of Neurological Disorders that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with American Neurological Association Board of Directors that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with Board of Directors, Association of University Professors of Neurology that is relevant to AAN interests or activities. Dr. Lucchinetti has a non-compensated relationship as a Member with Mayo Clinic Board of Trustees that is relevant to AAN interests or activities. Dr. Zalewski has nothing to disclose. Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for BMS Celgene. Ms. Cacciaguerra has received personal compensation in the range of \$500-\$4,999 for serving on a Speakers Bureau for Sanofi. Dr. Buciu has nothing to disclose. Karl Krecke has nothing to disclose. Dr. Messina has nothing to disclose. Dr. Bhatti has received personal compensation in the range of \$500-\$4,999 for serving as a

# Neurology®

## A Case of Recurrent Cerebral Cortical Encephalitis in MOG Antibody-Associated Disease

Laura Cacciaguerra, John J. Chen and Eoin P. Flanagan

*Neurology* 2022;99;S19-S20

DOI 10.1212/01.wnl.0000903180.06286.ba

**This information is current as of December 5, 2022**

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/99/23_Supplement_2/S19.full">http://n.neurology.org/content/99/23_Supplement_2/S19.full</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>Cerebrospinal Fluid</b> <a href="http://n.neurology.org/cgi/collection/cerebrospinal_fluid">http://n.neurology.org/cgi/collection/cerebrospinal_fluid</a> <b>CT</b> <a href="http://n.neurology.org/cgi/collection/ct">http://n.neurology.org/cgi/collection/ct</a> <b>Low pressure syndrome</b> <a href="http://n.neurology.org/cgi/collection/low_pressure_syndrome">http://n.neurology.org/cgi/collection/low_pressure_syndrome</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2022 American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

